Abstract: Novel compounds which are a glucocorticosteroid (GCS) chemically bound to a sugar, having the general formulaGCS.sup.1 --O--Sugar.sup.1for colon- or ileum-specific delivery of the GCS to inflamed bowel mucosa, as well as processes for their preparation, pharmaceutical preparations containing the compounds and the use of said compounds in therapy.

Abstract: Novel compounds which are a glucocorticosteroid (GCS) chemically bound to a sugar, having the general formulaGCS.sup.1 --O--Sugar.sup.1for colon- or ileum-specific delivery of the GCS to inflamed bowel mucosa, as well as processes for their preparation, pharmaceutical preparations containing the compounds and the use of said compounds in therapy.

Abstract: A hip joint prosthesis to be permanently anchored in a patient's hip is disclosed. The prosthesis comprises an attachment part for a ball unit designed to be anchored in the neck of a human femur. The attachment part comprises a primary fixture which may be an elongate anchoring element which is intended to be inserted into a channel extending through the femoral collum. The prosthesis also includes a secondary fixture for carrying a ball intended to be attached to the collum after removal of the head of the collum. The primary fixture and the secondary fixture are connected to each other. The prosthesis is preferably designed so that the length of the primary fixture terminates close to the head of the collum. The secondary fixture preferably comprises a plug-like part which is intended to be inserted in a cylindrical countersunk recess that is cut into the cancellous bone of the collum and which extends to the cortical bone in at least three locations.

Abstract: Combinations of 3'-azido-3'deoxythymidine and phsphonoformate have been found to produce a synergistic inhibitory effect against human immunodeficiency virus (HIV).

Abstract: The present invention relates to a DNA molecule containing intron sequences and encoding a human protein which is, depending on the site of action, called Bile Salt-Stimulated Lipase (BSSL) or Carboxyl Ester Lipase (CEL). The DNA molecule is advantageously used in the production of recombinant human BSSL/CEL, preferably by means of production in transgenic non-human mammals. The recombinant human BSSL/CEL can be used as a constituent of infant formulas used for feeding infants as a substitute for human milk, or in the manufacture of medicaments against e.g. fat malabsorption, cystic fibrosis and chronic pancreatitis.

Abstract: Compounds of the general formula (I), ##STR1## in which formula the 1,2-position is saturated or is a double bond, R.sub.1 is hydrogen or a straight or branched hydrocarbon chain, R.sub.2 is hydrogen or a straight or branched hydrocarbon chain, R.sub.3 is acyl, X.sub.1 is hydrogen or halogen, X.sub.2 is hydrogen or halogen and provided that 1) R.sub.1 and R.sub.2 are not simultaneously hydrogen, 2) X.sub.1 and X.sub.2 are not simultaneously hydrogen, 3) when the 1,2-position is a double bond, R.sub.1 and R.sub.2 are not simultaneously methyl groups, 4) when the 1,2-position is a double, R.sub.1 is a hydrogen atom and R.sub.2 is a straight or branched hydrocarbon chain having 1-10 carbon atoms R.sub.3 is acyl having 11-20 carbon atoms, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in the treatment of inflammatory and allergic conditions.

Abstract: The invention concerns compounds of the formula 1 ##STR1## and pharmaceutical compositions containing the compounds as active ingredients. The peptides of the invention are .delta. opioid receptor antagonists and are useful as analgesics and immunosuppressants.

Abstract: The invention concerns the compound of the formula: ##STR1## and protected forms and salts thereof which serve as starting materials in an improved method of synthesizing serine protease inhibitors. The invention further concerns an improved method for synthesizing serine protease inhibitors which utilizes the compounds.

Abstract: The invention consists of a combination of a substance that increases the intragastric pH and an acid degradable antibacterial compound. By this combined product regimen it will be possible to obtain maximal local antibacterial effect of acid degradable antibiotics as well as enhanced bioavailability of the active antibiotic, thus resulting in higher amounts of the active compound in the gastric mucosa due to secretion of weak bases. Both pharmacological effects contribute to drastically increased antimicrobial capacity of acid degradable antibiotics to be used against local infections in the gastrointestinal tract causing gastritis and/or peptic ulcer. The invention also selects to the use of said combination and a process for the preparation thereof.

Abstract: The present invention relates to a method for the synthesis of foscarnet, i.e. trisodium phosphonoformate hexahydrate, comprising the steps of adding sodium hydroxide to water, heating the aqueous sodium hydroxide solution to 50.degree. C., adding triethyl phosphonoformate to said solution at 50.degree. C., heating the reaction mixture to reflux for about 1 hour, cooling of the reaction mixture and filtering-off of the product.

Abstract: The present invention relates to an oxindole compound having the formula 5-cyclohexyl-1,3-dihydro-1-[2-[4-(phenylmethyl)-1-piperazinyl]ethyl]-2H-in dol-2-one for the prevention or treatment of cognitive dysfunctions.

Abstract: A galanin antagonist which is a galanin receptor ligand is described. New peptides, Galanin (1-12)-Pro-Substance P(5-11), Galanin (1-12)-Pro-Bradykinin(2-9), Galanin (1-12)-Pro-Pro-Pro- (Leu.sup.5 -Enkephalin (5-1), Galanin (1-12)-Pro-Lys(.epsilon.-NH-)Pro-(Leu5-Enkephalin (5-1) and functional analogues and functional derivatives thereof are disclosed. The peptides are used in pharmaceutical preparations to treat a disorder in a mammal which depends on the physiological function of galanin at the galanin receptor.

Abstract: A process for providing water-soluble micronized pharmaceutically acceptable inhalable substances, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation of the pharmaceutically acceptable substances. This process is carried out by the steps of reducing, if necessary, the residual water from the micronized substance by drying at an elevated temperature and/or vacuum; conditioning the dried, micronized pharmaceutically acceptable inhalable substances with a solvent; and eliminating residual solvent by storing under dry conditions as, e.g., in a vacuum or by purging with a dry, inert gas.

Abstract: The present invention relates to a novel process for the manufacture of (22 R,S)-16.alpha., 17.alpha.-butylidenedioxy-11.beta., 21-dihydroxypregna-1,4-diene-3,20 dione (I) by reacting 11.beta., 16.alpha., 17.alpha. 21-tetrahydroxypregna-1,4-diene (II) with butanal, CH.sub.3-- CH.sub.2 --CH.sub.2 --CHO, in acetonitrile in presence of p-toluenesulphonic acid as a catalyst.

Abstract: The present invention relates to a process for the preparation of compounds of general formula (I), wherein R stands for a straight chained C.sub.

Abstract: The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and selected from H, alkyl, aryl and arylalkyl; X and Y are the same or different and selected from alkoxy, aryloxy, alkyl, alkylthio, arylthio, fluoroalkyl, halogen, cyano, OSO.sub.2 CH.sub.3, OSO.sub.2 CF.sub.3, OCF.sub.3 and SCF.sub.3 with the proviso that the compound of formula I wherein R.sup.1 and R.sup.2 =H, X=Br and Y=Me is excluded;or a pharmaceutically acceptable salt thereof, methods and intermediates for their preparation, novel pharmaceutical compositions and the use thereof for inhibiting the enzyme 3-hydroxyanthranilate oxygenase, 3-HAO, responsible for the production of the endogenous neurotoxin quinolinic acid, QUIN.

Abstract: Compounds of the formula I ##STR1## processes for their preparation, pharmaceutical preparations, use of and method of treatment of disorders in CNS by using compounds of formula I.

Abstract: A process for the production of guanidino protected .omega.-aminoalkyl guanidines comprising reacting a diamine selectively at one amino group with an alkoxycarbonyl or aralkoxycarbonyl protected electrophilic guanylation reagent. The process of the invention is general and may be performed efficiently in one step yielding a product with high purity and in useful yields. The invention further refers to some compounds that are novel per se and to some novel compounds useful in the process of the invention.

Abstract: The invention relates to a method for treating the surface of surgical implants made of titanium or a titanium alloy, for instance dental implants, before implantation in bone tissue. The method results in a roughened exterior implant surface and at the same time a cleaning action is obtained, should there be any contaminants. The surface is blasted with particles of an oxide of titanium, preferably titanium dioxide. In this way an implant having an improved retention in bone tissue is obtained. The blasted implant is used in a method for treating toothlessness.